Cyclerion Therapeutics. has been granted a patent for novel processes to prepare high-purity compounds that stimulate soluble guanylate cyclase (sGC). The methods allow for large-scale production and include novel intermediates, enhancing efficiency in manufacturing these compounds. GlobalData’s report on Cyclerion Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cyclerion Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Cyclerion Therapeutics's grant share as of July 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Process for preparing soluble guanylate cyclase stimulators
The granted patent US12030874B2 outlines a series of processes for preparing specific chemical compounds, particularly those represented by Formula IB, IC, and ID. The claims detail various methods for synthesizing these compounds, including the use of specific reactants and conditions. Notably, the processes involve the reaction of dibromopyrimidine and carboxylic acids, as well as the use of n-butyllithium as a base. The patent also specifies the preparation of compound derivatives and includes crystallization steps to yield distinct crystalline forms, such as Form B of compound ID.
Additionally, the patent describes a crystallization process that involves dissolving the compound in a solvent mixture of acetonitrile and water, followed by a series of heating, filtering, and cooling steps to achieve the desired crystalline form. The claims further elaborate on the use of N,O-dimethylhydroxylamine in conjunction with various acids to facilitate the formation of specific derivatives. The patent emphasizes the importance of precise conditions, such as temperature ranges and the choice of acids, to ensure successful synthesis and crystallization of the compounds. Overall, the claims provide a comprehensive framework for the preparation of these chemical entities, which may have potential applications in various fields.
To know more about GlobalData’s detailed insights on Cyclerion Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
